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 ABSTRACT 
 
Childhood cancers show fundamental differences to most common adult solid tumours in their 
cancer-causing genetics, cell biology and their local tissue microenvironment. Effective 
treatments will be attainable when the molecular events that are specific to childhood 
tumourigenesis are better understood. However, it is in this context critical to consider both 
species and developmental aspects when looking for the relevant signalling. An influence from 
the microenvironment on clonal dominance is likely contributing to the disparity between 
primary and metastatic tumours seen in many patients, as well as inter-tumour heterogeneity 
between patients with the same tumour type. 
In this thesis a novel concept is presented for preclinical studies of embryonic tumours in a 
recently described humanised model. Benign human experimental teratoma was generated in 
NOD SCID gamma (NSG) mice from diploid bona fide pluripotent stem cells (the PSCT 
model). An abundant presence of developing early neural components suggests this human 
embryonic model to be uniquely suited for in vivo transplantation studies of primitive 
neuroectodermal tumours originating early in life.  
Following transplantation of tumour cell lines (Paper I), or patient biopsy material (Paper II) 
the initial microcolonisation showed a tumour type specific tissue tropism in that growth was 
instigated into specific embryonic tissue compartments, constituting the preferred cellular 
context/niche supporting initial colonisation and expansion. The phenomenon of 
microcolonisation reflects in this context an ability of tumour cell clones to comply or adapt to 
new environments, a feature which has great impact on metastasis and clinical prognosis.  
Chemotherapy is widely accepted as part of first-line therapy for high-risk paediatric 
neuroblastoma. In a third study (Paper III) we have examined chemotherapy 
responsiveness/resistance of neuroblastoma in the PSCT model. Two well-characterized 
neuroblastoma cell lines were subjected to chemotherapy using the anthracycline drug 
doxorubicin and we report for the first time in situ studies performed in a human homologous 
embryonic in vivo microenvironment. Here we combined classical histopathology with high 
throughput single cell screening for preclinical drug evaluation. Using laser scanning cytometry 
for screening of chemotherapy-induced changes of nuclear DNA index (sub G1 fraction), in 
combination with immunohistochemistry and cytology for proliferation, apoptosis and cell 
death, we could demonstrate dose dependent and diversified responses to single-dose regimens 
of doxorubicin. Following a recurrent doxorubicin regimen (repeated administration with 48h 
interval), we observed the presence of an asynchronous response within individual tumour 
colonies, with cells exhibiting cytotoxic effects or enhanced proliferative index.  
The results illustrate the feasibility of the approach and are encouraging for clinically relevant 
studies of patient material regarding intra tumour heterogeneity and asynchronous response to 
therapy. Furthermore, the findings demonstrate several important advantages using the PSCT 
model compared to employing conventional preclinical in vivo models and lead us to propose 
that the use of this human embryonic microenvironment is a well-needed complement for 
preclinical in vivo studies of primitive neuroectodermal tumours originating early in life. 
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1 INTRODUCTION 
 
1.1 Cancer 
 
The word cancer originates from the Greek word Καρκινος (crab) and was initially used 
by the famous physician Hippocrates (460–370 B.C) the “father” of medicine. Cancer is 
today used to denote tumours derived from epithelial tissues.   
 
The conceptual definition of a tumour is an abnormal growth of cells, dysregulated in 
the balance of cell proliferation and cell death. This is commonly due to multiple 
genomic or epigenomic changes resulting in populations of cells with acquired 
properties beyond dysregulated growth, including ability to invade, migrate and 
metastasise at distant sites. The tumour will need to evade the host control system and 
induced cell death. In 2000 Hanahan and Weinberg published a review describing how 
cancer can acquire these capabilities through various strategies; the 6 hallmarks of 
cancer; 1: Self-sufficiency in growth signals, 2: Insensitivity to growth signals, 3: 
Tissue invasion and metastasis, 4: Limitless replicative potential, 5: Sustained 
angiogenesis and 6: Evading apoptosis (Hanahan and Weinberg 2000). In 2011 these 
authors further developed the theory and added two emerging hallmarks; 7: Avoiding 
immune destruction and 8: Reprogramming energy metabolism (Hanahan and 
Weinberg 2011 - Figure 1). They also described two enabling cancer characteristics; 9: 
Tumour promoting inflammation and 10: Genome instability and mutation.  The 
assumption is that “most cancer has acquired the same set of function capabilities 
during their development, albeit through various mechanistic strategies“. 
 
Figure 1. Hallmarks of cancer – Next generation.  
Reproduced from Hanahan and Weinberg 2011, with permission from publisher. 
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Tumours are often categorised by site of origin, but can also be separated by histo-, or 
cytopathology and more recently by molecular characteristics. Tumours are furthermore 
divided into malignant and benign phenotypes. Cells in a malignant tumour can invade 
the surrounding tissue or spread as metastases while cells in a benign tumour do not.  
 
The many aspects of cancer vary strongly between categories. Individual variations 
seen in cancers with similar origin strongly affect the outcome and the possibilities or 
difficulties for treatments. A personalized approach has been proposed both for 
diagnosis and treatments. The story of cancer is a complex case, one can speculate that 
perhaps the search for origin and treatment will continue as an unsolved dilemma only 
flavoured by further layers of complexity. Nonetheless, crucial breakthroughs have 
been made and the field of cancer therapy has flourished the last 50 years. 
 
According to the WHO cancer report 2014 cancer is among the “leading case of 
morbidity and mortality world wide with approximately 14 million cases and 8.2 
million cancer related death in 2012”, these numbers are expected to rise over the next 
two decades with about 70% (http://www.who.int/topics/cancer; Accessed Feb 2015)  
 
 
1.2 Childhood cancer 
 
Although less common than in adults, only approximately 300 children are diagnosed 
with a malignant disease every year in Sweden, cancer is the primary cause of death in 
children 1-15 years of age in Sweden (Gustafsson et al. 2013). Apart from differences 
in age and incidence there are fundamental differences between childhood and adult 
cancer with regard to cell of origin, genetic aberrations, epigenetic features and the 
tumour environment (Scotting et al. 2005). Adult cancer is dominated by carcinomas, 
whereas >50% of all childhood cancers consist of haematological or CNS malignancies 
(Fig 2, from Gustafsson et al. 2013, see also Stiller 1994). The cancers of childhood 
frequently arise in immature tissue environments and the progenitor cell resulting in 
cancer may be at another developmental state indicating that childhood cancer may be 
considered a developmental disorder. Considering the time aspect, the causing events 
and triggering of cancer are supposedly different between childhood and adult cancer. 
The childhood cancer cell has been proposed to develop with fewer defects in its cell 
regulatory process compared to adults. (Scotting et al. 2005) and recently sequencing 
data have shown that pediatric malignancies carry significantly less mutations than 
adult malignancies (Alexandrov and Stratton 2014). 
 
During the prenatal period of human postnatal development there are strongly regulated 
processes for tissue growth and differentiation, involving complex cellular processes to 
time the precision of mitosis and apoptosis, where and when. This suggests a close link 
between organogenesis and susceptibility to oncogenic transformation (Scotting et al. 
2005).  
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Figure 2. Distribution of childhood malignancies in Sweden diagnosed 1984-2010 <15 years of age at 
diagnosis (n=7065). Diagnoses are stratified according to the WHO ICCC3 classification from 2005. 
Leukemias, lymphomas and CNS tumours constitute 70% of the children, and the other nine diagnoses 
account for 30%, with carcinomas only ~2%. Reproduced from Gustafsson et al.  2013, with 
permission from the publisher. 
 
The genetically unique features for childhood cancer may be due to, or linked to their 
developmental phase and they may inherit similar immature properties, thus possibly 
providing a shorter route for tumour development. This is in contrast to the adult 
where progeny of mature tissues are set for differentiation and sensitivity for 
apoptosis. Thus the “multi hit” on DNA damage is key in adult cancer (Knudson et al. 
1992). It is important to keep this in mind when treating cancer and developing cancer 
therapy for the child.  
The differences in biology with childhood cancers being more sensitive to treatment, 
and children being less sensitive to side effects, in particular short term toxicity from 
chemotherapy, has allowed the development of better treatment and improved 
survival for children with cancer during the last decades (Figure 3). 
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Figure 3. Childhood cancer prognosis in Sweden (5-year survival) over time for different, selected 
diagnostic groups. Prognosis improved considerably during 1970-1995. The results during the last 
decades seem to have reached a plateau, although survival for neuroblastoma and CNS-tumours have 
continued to improve. Reproduced from Gustafsson 2013, with permission from the publisher. 
1.3 Pluripotency in normal and abnormal development 
 
Pluripotent stem cells (PSC) are unique in their capacity for self-renewal and to sustain 
an undifferentiated state, but also in that they maintain a capacity to differentiate into 
any cell derived from the three germ layers of the embryo, endoderm, mesoderm and 
ectoderm. (Thomson et al.1998). Pluripotency in mouse stem cells has been divided 
into two separate states; naıve and primed (Nichols et al. 2009). Interestingly, recent 
studies of the signalling pathways to induce pluripotency have revealed separate 
principles between mice and humans (Tesar et al. 2007; Schnerch et al. 2010) Such 
findings are intriguing considering the historical impact of mouse studies for our 
understanding of human early development. Furthermore, these findings are of vital 
importance also for cancer research since stem cell-like characteristics have been 
convincingly linked to drug resistance and metastasis in both mouse and human 
malignancies (Riggs et al 2013; Lee et al. 2013) This emphasis the huge significance of 
complementing current in vivo mouse studies of human cancer with models adapted to 
homologous cell-cell interactions for studies on signalling pathways.     
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Following the initial report on pluripotency of cultured human embryonic stem cells 
(hESC), (Thomson et al. 1998), standardized protocols for quantitative in vitro 
assessment has been an important objective (Muller et al. 2011). For the full biological 
understanding of pluripotency complementary assessment in vivo is also necessary, e.g. 
for safety in regenerative medicine, or to quality assure new PSC lines. For this analysis 
the formation of experimental teratoma following xeno-transplantation into 
immunosuppressed animals is so far the only feasible option, often considered as a 
“golden standard” (Brivanlou et al. 2003; Gertow et al. 2007; Adewumi et al 2007). In 
2004 our research group published the first more detailed analysis of experimental 
teratoma (Gertow et al. 2004), later followed by a kinetic analysis showing the 
embryonic process of experimental teratoma from the human embryonic stem cell line 
HS181 (Gertow et al. 2011). 
 
 
Figure 4. Neural crest cells and derivates in mesoderm/ectoderm. During early development after the 
process of neurulation the neural crest cells gain motile property and migrate out and differentiate into 
a variety of cell types, including neurons and progenitors of sympathetic nervous system. Here a 
subpopulation may gain potential to drive NB formation - or other tumours of neuroectodermal origin. 
Reproduced with the permission of D. Widera. 
http://web.biologie.unibielefeld.de/cellbiology/index.php/research/neural-crest-derived-stem-cells  
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1.4 Neuroectodermal tumours 
 
Embryonic tumours occurring in the central or peripheral nervous system, here 
collectively denoted embryonic neuroectodermal tumours, are known to be heterogenic 
between individuals and for intra-tumour subpopulations of cells with biological 
features responsible for aggressive metastatic behaviour and resistance to therapy 
(Brodeur 2003; Gilbertson et al 2004). 
The PSCT embryonic microenvironment with an abundant presence of developing 
neural components, overlapping with gestation stages immediately preceding the 
positioning of adrenal sympatical progenitors in embryonic mesenchyme, suggests the 
PSCT model to be uniquely suited for in vivo studies of primitive neuroectodermal 
tumours originating early in life (Gertow et al 2011; Hultman et al 2014).  
The group of embryonic neuroectodermal tumours includes among other tumours 
neuroblastoma (NB) (studied in Papers I and II) and the pPNET and sPNET (peripheral 
and supratentorial primitive neuroectodermal tumours – included in Paper II). In this 
thesis there is focus on NB, mainly for practical reasons, with the availability of 
adequate cell lines (Paper I and III) and due to access of patient tumour material (Paper 
II).  
 
1.4.1 Neuroblastoma   
    
Neuroblastoma (NB) was first described in 1864 by Rudolf Virchow as an extra cranial 
solid embryonal tumour called “glioma”, first in 1910 it was called neuroblastoma 
when the similarities of tumour cells with embryonic adrenal medulla and migrating 
sympathetic neuroblasts were described (Wright 1910). Subsequently both biological 
and clinical features have been investigated and described in detail (as reviewed by 
Brodeur 2003 and Maris 2010). NB is the most common malignancy in the neonatal 
period when genetic predisposition is most significant (Orbach et al. 2013) and 
accounts for >20% of neonatal cancers and in total 5.5% of childhood cancers and 9.2% 
of childhood cancer deaths (Johnsen et al. 2009). 
Half of the NB cases occur in children under 18 months of age, in support of the notion 
that this is a tumour of embryonic origin. NB is considered to stem from precursors of 
the sympathetic nervous system of the ganglionic lineage, with tumours arising in 
sympathetic ganglia or adrenal gland (Grimmer and Weiss 2006). 
NBs are highly heterogenic between individuals with regard to genetics and histology, 
with a unique ability to spontaneously regress or differentiate (Bénard J et al. 2008; 
Brodeur 2003; Brodeur and Bagatell 2014). Spontaneous regression is however mainly 
observed in patients under one year of age (Schwab et al. 2003), interestingly 
mimicking the developmental process where prenatal neurons undergo programmed 
cell death at the prenatal stage. This indicates that the NB genetic profile is linear 
specific and developmentally regulated with links between NB and embryonic neuronal 
development at molecular level (Grimmer and Weiss 2006).  
High-risk NB may on the other hand adapt to the microenvironment leading to 
aggressive metastatic tumours (bone marrow and bone are most common) (Maris 2010, 
Brodeur 2003). The majority of primary NB arises in the abdomen, along the 
sympathetic ganglia and in the medulla of adrenal glands (Maris et al. 2007) but 
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tumours have also been observed in the neck, chest and abdominal or pelvic regions. 
The figure below illustrates the metastatic preferences of NB (from Maris 2010). 
 
 
 
Figur 5. Illustration of neuroblastoma and potential locations of tumour lesions.  
From Maris 2010. Reproduced with permission from Massachusetts Medical Society. 
 
1.4.2 Neuroblastoma staging and classification  
 
The International Neuroblastoma Staging system (INSS) was presented in 1988 to unify 
intentional criteria in confirmation of diagnosis and response to treatment, defined as 
the International NB response criteria (INRC) (Brodeur 1993).   
According to the INSS system NB is categorized into stages 1, 2, 3, 4 and 4S tumours 
(Brodeur et al.1993).  Ranging from the less aggressive NB stage 1 tumours which are 
localized without metastasis and can be surgically removed to the highly aggressive 
stage 4 tumours commonly found in older children that exhibit metastatic spread and 
often show treatment resistance to chemotherapy. Stage 4S NB have rather unique 
tumour features that are manifested in infants under one year of age having a localized 
tumour with e.g. metastasis in skin, liver or bone marrow, but with a possibility to 
spontaneously regress completely or respond very well after minimal therapy. (Brodeur, 
2003; Maris 2010, 2007). 
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Since the INSS system is based on post surgical evaluations there is a risk for over 
staging patients towards high-risk staging, thus there is a dependency on surgical 
assessment and skill. In 2009, this drawback was addressed, by the international NB 
risk group INRG who presented an alternative system based on Image defined risk 
factors (IDRF). This system categorizes patients in different stages depending on 
presence of metastatic spread (M) or the tumour being localised without (L1) or with 
IDRF (L2), also with a special metastatic stage MS – previously called 4S limited to 
children below 18 months of age at diagnosis having a favourable pattern of spread 
(excluding bone, lung and CNS)  (Monclair et al. 2009). Together with other prognostic 
factors this renders a pre-treatment risk stratification system. To establish complete 
classification several additional parameters are needed including patient age, tumour 
genetics and tumour histology, separating NB patients into very low, low, intermediate 
and high-risk groups (Cohn et al. 2009).  This will guide the treatment based on the 
evaluation if the cancer, if it is of favourable or an unfavourable nature and the child at 
risk of treatment response or treatment resistance and relapse.  
 
1.4.3 Neuroblastoma genetic profiling 
  
Neuroblastoma clinical heterogeneity is due to biologic features, mainly a wide 
heterogeneity of tumour genetics. However, there are still many uncertainties 
regarding the genetic basis of NB. Embryonic neural tumours have so far not been 
shown to entail any single dominant or shared essential genetic aberration within the 
tumour group (reviewed by Johnsen et al 2009 and references therein). However, for 
children with high-risk NB and poor prognosis several patient specific mutations and 
gene amplifications have been identified, such as amplification or overexpression of 
MYCN (Brodeur 2003), deletions of parts of chromosome arms 11q (Caren et al. 
2010), or mutations in the anaplastic lymphoma kinase (ALK) gene (Mosse et al. 
2008; Maris 2010). 
 
MYCN is a transcription factor and a member of the MYC family of proto-oncogenes 
that regulates expression of several target genes (reviewed by Adhikary and Eilers 
2005). This regulation is involved in monitoring of diverse fundamental cellular 
processes, e.g. dedifferentiation, cell growth, proliferation, protein synthesis, 
metabolism and apoptosis. This provides a dual nature, being able to drive both 
cellular proliferation as well as sensitizing cells to programmed cell death 
(Westermark et al. 2011; Albihn et al. 2010). Transgenic expression of MYCN has 
been shown to result in neuroblastoma (Weiss et al. 1997). MYCN is developmentally 
restricted during the early stages of ontogeny and is important for proliferation and 
migration of the neuroblast of neural crest (Lu et al. 2003). In tumours with amplified 
MYCN, the amplification may be 3 to 300-fold. This amplification frequently leads to 
an overload of transcribed MYCN and increased cellular proliferation and decreased 
apoptosis. This leads to a poor differentiation of the cancer cells, as well as triggered 
vascularity driving the tumour progression. The amplification may be identified as 
both homologous and heterologous spread in the patient and may vary from primary 
site to metastatic areas (Schwab 1993; Brodeur et al 1988). MYCN amplification is 
found at all stages of NB, but dominates in the M stage and is strongly associated with 
bad prognosis of high-risk NB patients (Brodeur 2003). 
 
 
 
  13 
8 
The transmembrane receptor tyrosine kinase (ALK) is expressed in the central and 
peripheral nervous system (Chiarle et al. 2008). ALK mutations are today known to 
be a cause for hereditary NB, identified in NB pedigrees (Janoueix-Lerosey et al. 
2008; Mosse et al. 2008) and also found to be mutated in sporadic NB up to 10% 
(Fisher and Tweddle 2012). Interestingly, besides ALK-mutations present in most 
cases of familial NB also PHOX2B mutations have been found in families with 
neuroblastoma and linked to the presence of ”neurocristopathies” such as congenital 
central hypoventilation syndrome (CCHS) and Hirschsprung’s disease caused by 
neural crest cell migrative failure  (Mosse et al. 2004; Trochet et al. 2004).  
 
The loss of sequences on chromosome 11q is a predictive factor for the outcome of 
MYCN non amplified L stage NB tumours (Brodeur 2003; Maris et al 2007) and also 
defining a group of high-risk tumours with genetic instability distinct from the 
MYCN-amplified tumours (Caren et al. 2010).   
  
In summary, most NB tumours show mutations or segmental genetic aberrations 
usually linked to poor outcome including MYCN-amplification, ALK-mutations and 
11q-deletions as well as other common aberrations including 17q gain or 1p deletions 
and a large variety of other oncogenic changes (Maris 2010; Caren et al 2010). NB 
with favorable prognosis usually show only numerical chromosomal aberrations 
(Maris 2010; Caren et al. 2010; Brodeur and Bagatell 2014). 
 
 
 
Figure 6. Schematic overview of MYCN interplay and therapy target strategies for MYCN and ALK, 
relevant in neuroblastoma. Reproduced from Barone et al 2013 with permission from the publisher. 
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1.5 Preclinical tumour models  
 
The choice of model depends primarily on the scientific question, available resources 
and time.  
The most widely used model of human cancer - in vitro studies (from the Latin word 
“in glass”), is a convenient and manageable approach but limited by the rudimentary 
mimicry of the full context in the host. The addition of 3D-cultures is an improvement ( 
reviewed by Tanner and Gottesman 2015). In vitro models are still widely used and a 
relevant base for tumour research, but with obvious limitations e.g. due to the lack of 
context from the host influence as the metabolic system, vascularization and 
microenvironment, etc.  
In silico studies (computer based research and modelling) is today gaining ground in 
step with the technological advancement, nonetheless in vivo studies are essential.   
Animal models have been widely used in biological and medical research. In the mid 
1950´it was documented that tests in vivo were more predictive for clinical response 
than in vitro tests (Suggitt and Bibby 2005). Animal research (dominated by studies in 
rodents), have lead to possibilities to assess advantages and side effects of drugs in vivo 
before applying them to human patients. The clinical track record from this type of 
analysis, i.e. attrition rate in clinical trials in oncology, is however disappointing 
(Hutchinson and Kirk 2011; Norris and Adamson 2012).  
Recent findings have revealed differences between human and mouse species for the 
signalling pathways controlling the induction of cellular potency (Nichols and Smith 
2009; Brons et al. 2007; Tesar et al. 2007). Since the processes of cancer progression 
have been linked to induction of cellular potency (Nguyen et al. 2012; Easwaran et al 
2014), the use of mice for studies of human cancer could be challenged, and 
emphasizesthe the importance of using humanized models. 
 
1.5.1 Syngeneic models 
Syngeneic mouse tumour models were first introduced in the 1930th with the use of, at 
the time, newly introduced inbred mouse strains. In syngeneic tumour models the host 
and the tumour are histocompatible and the host immune system is not necessarily 
compromised, although many models rely on reducing the innate immune system. 
 
1.5.2 Xenograft models 
The definition of xenografts originates from the Greek word ξένος (“foreign”) and 
relates to e.g. transplantation of a human tumour to an animal, i.e. over the species 
barrier. In contrast to the syngeneic models, a xeno-transplantation relies on 
compromising the immune system to avoid rejection in the host animal. This model 
system is well established and the access to severely immunodeficient animals permits 
reducing interference with the immune system allowing for transplantation 
resistance/acceptance. 
Heterotopic xenografts  
This indicates that the tumour graft is placed in an abnormal location, for example sub 
cutaneous injection of neuroblastoma (s.c).  
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Orthotopic xenografts 
This defines engraftment at the tumour type specific site of origin. Except for species 
differences, this allows for an organ specific local environmental influence. This 
approach is generally regarded to provide a more relevant environment compared to 
heterotopic transplantation (Kanna et al. 2002). The first orthotopic NB model was 
described in 1994 (Flickinger et al. 1994).  
 
Patient derived Xenograft models 
Patient-derived tumour xenograft (PDX) models are generated by xenotransplantation 
of fresh human tumour material and are considered clinically predictive (Das Thakur et 
al. 2014). An alternative to conventional xenograft models using cell lines, or PDX 
models using fresh tumour, is to use low passage numbers of patient-derived tumour 
tissue (for example removed from the patient and passaged as xenograft or in vitro as 
cell cultures, for a very short period of time). The low passage is believed to conserve 
original tumour characteristics. 
 
1.5.3 Genetically engineered models (GEM’s)  
Rudolf Jaenisch demonstrated the first genetic engineering of mice in 1974 by inserting 
viral DNA into an early stage mouse embryo (Jaenisch and Mintz 1974).  Later, the 
classical transgenic mouse model was constructed by pronuclear injection of cDNA 
constructs containing promoter elements this was followed by research and 
collaborations from a large number of research groups (Gordon and Ruddle 1981; 
Costantini et al. 1981; Brinster et al. 1981) and in transgenic mouse models of today, 
the genetic modification may be an insertion of a new gene sequence or 
deletion/alteration stimulating the induction and growth of the cancers of interest, 
ideally confined to the relevant tissue environment (Teitz et al. 2011).  The first report 
of a GEM model for NB came in 1990, showing pre-neoplastic lesions in the adrenal 
medulla and NB like tumours from a transgene insertion of polyoma virus T antigen 
under the control of the thymidine kinase promotor (Aguzzi et al. 1990). As mentioned 
above, MYCN amplification is associated with high-risk NB and poor prognosis 
(Brodeur et al. 1988). In 1997 a transgenic mouse model was generated with 
overexpression of MYCN from the tyrosine hydroxylase promotor providing a neuronal 
preference specifically expressed in neural crest and peripheral nerves of 
parasympathetic ganglia and adrenal medulla (Weiss et al. 1997). Although these 
models will develop NB with high resemblance to the human counterpart regarding 
morphology and site of origin, they do not fully mimic the human clinical picture due to 
species differences in the genome and crucial divergences of regulatory elements, 
metabolic processes that vary between humans and mice, e.g. described in the 
”ENCODE” project (encyclopedia of DNA elements -The mouse ENCODE 
consortium; 2014). Thus there is a need for new models also specifically for NB.   
 
1.5.4 Humanised models for childhood cancer  
To be straightforward – the best place to study murine tumours and interactions with 
murine stroma is in a mouse, and the best model for studies on human tumours and 
interaction with human stroma is hypothetically in humans. The latter presents of 
course a challenge for experimental applications, and new models are needed, since in 
the end it is human patients we strive to treat, not mice. 
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The design of GEM models may include the transgenic expression of selected entire 
human genes, in order to humanize metabolic or glycosylation enzymes, telomere 
structure, or the immune system (Frese and Tuveson 2007).   
Humanised mice with regard to the hematopoietic system, for reconstitution of a human 
immune response to the tumour, have been obtained by injection of human peripheral 
blood, or human CD34+ hematopoietic stem cells from human umbilical cord blood 
(Shcultz et al. 2007, 2012). The methodology for hematologic reconstitution in 
humanized mice is still under perfection and reconstituted immune cells are 
quantitatively/qualitatively weak and also fail to be maintained over long-term, but 
improvements are reported (Bernard et al. 2008; Shultz et al. 2012).  
 
1.5.5 The pluripotent stem cell teratoma (PSCT) model 
 
This thesis explores the use of a human embryonic in vivo model based on 
experimental benign teratoma, here applied to studies of primitive neuroectodermal 
tumours originating early in life. Experimental teratoma has emerged as an alternative 
approach for in vivo modelling of intercellular interactions between developing tissues 
and cancer cells (Tzukerman et al. 2003, 2006; Cedervall et al. 2009; Katz et al. 2009; 
Burgos and Ojeda 2013; Abelson et al. 2013; Jamil et al. 2013, 2014). The pluripotent 
stem cell teratoma (PSCT) model belongs to a new generation of models, 
complementing conventional xenografts, in that it provides a human embryonic 
microenvironment (Tzukerman et al 2003, reviewed by Hultman et al. 2014). Similar 
to PDX models the PSCT platform requires immunodeficient hosts, but with the vital 
difference of supplying interaction with human microenvironment. 
Protocols for the generation of human experimental teratoma by the injection of 
pluripotent stem cells have been described in detail for various heterotopic sites; e.g. 
intramuscularly, subcutaneously, under the kidney or testis capsule (Gertow et al. 
2007). In this thesis, the route of intra testicular injection was used. This choice was 
selected due to several reasons – testis is immune-privileged, not vital for sustaining 
health of the mice, encapsulated to keep the graft in place and it is easily accessible and 
thus convenient for palpation. For ethical reasons, teratoma development was limited to 
a total size of 1,5 cm in order not to negatively affect the mouse host. 
 
1.5.5.1 Embryonic and oncofetal nature of experimental teratoma 
Mature benign experimental teratomas, derived from pluripotent stem cells with normal 
karyotype (the PSCT model), represent a benign growth that can be described as a 
chaotic embryonic process, lacking structural axis (Gertow et al. 2004, 2011; Lensch et 
al. 2007).  Under standardized conditions such experimental growths consist of a 
reproducible microenvironment with a rich blend of embryonic tissues including early 
organoid development, as well as immature neural components (FIGURE 5 - Gertow et 
al. 2004, 2011). These benign immature components exhibit strong morphological 
resemblance with tumours of embryonic neuroectodermal origin (Cedervall et al. 2011), 
and when similar histopathology is present in patient samples they are considered 
potentially malignant. Nevertheless, in the embryonic model such findings are part of 
early development and the shared histology is the basis to our study of neuroectodermal 
tumours implanted into matching PSCT microenvironments. 
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Figure 7. Experimental teratoma time alignment with human development.  
Reproduced from Gertow et al. 2011 with permission from the publisher.  
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1.5.5.2 Propagation of human tumours in the PSCT model 
 
Tzukerman and collaborators were first to report the use of PSCT as a transplantation 
model for human tumours (Tzukerman et al. 2003). In a series of studies they studied 
the growth from a panel of different cancer cell lines originating from; glioma, prostate, 
breast, lung and colorectal cancer, but more importantly also from primary ovarian 
cancer, as well as short term cell lines from these types of cancer. Comparing 
transplantation into teratomas with conventional xenografts, they reported an improved 
and increased survival rate of the human tumours in the human model system. They 
also found differences in growth, invasion, and angiogenic responses. This research 
group also used the model to test effects of immunotherapy with a recombinant 
immunotoxin antibody against A431 directed against epidermoid carcinoma cell–
related epitopes (Tzukerman et al. 2006). Intriguingly, while this therapy was effective 
in a conventional immunosuppressed murine xeno-model, the same immunotherapy 
failed to eradicate the tumour in a hESC growth environment (Tzukerman et al. 2006). 
This indicated differences between xenografts and the PSCT model in tumour 
behaviour and therapy response.  
Cedervall et al studied a human cutaneous malignant melanoma cell line in the PSCT 
model (Cedervall et al. 2009). While the resulting histology was generally analogous 
compared to parallel xenografts, an additional de-differentiated melanoma phenotype 
was observed in PSCT model, not detected in xenografts This finding together with 
observations of abundant early neural development in experimental teratoma raised to 
us the prospect that the microenvironment in PSCT could be better matched for tumours 
originating early in life, and in particular tumours of neural origin. This hypothesis was 
further explored in Paper I with a study of neuroblastoma cell lines transplanted to the 
PSCT model. 
  
1.6 The Tumour microenvironment 
 
The development of malignant solid tumours requires a microenvironment that supports 
the uncontrolled proliferation and spread of cancer cells and also conditions that avoid 
destruction from the various arms of the immune system must be present. The tumour 
microenvironment (TME) consists, in addition to tumour cells, of non-cancerous cells 
that include endothelial cells and pericytes to support the growth of blood vessels, 
fibroblasts, lymphoid cells and cells of the myeloid linage as well as signalling 
molecules and an extracellular matrix that support tumour cell growth (Quail and Joyce 
2013; Hanahan and Coussens 2012; Hanahan and Weinberg 2011).  
 
During tissue injury residential fibroblast differentiate into myofibroblasts. These cells 
also called cancer associated fibroblasts (CAFs) are abundantly presented in the TME 
(Sugimoto et al. 2006). CAFs secrete various growth factors important for cancer cell 
proliferation including TGF-β that may induce epithelial-mesenchymal transition 
(EMT) of tumour cells and contribute to the immunosuppressive conditions seen within 
TMEs (Erez et al. 2010). CAFs also produce chemokines, including CXCL12 that 
stimulate malignant cell growth and function as a chemoattractant to stimulate 
migration of other stromal cell types and their progenitors into the TME (Orimo et al. 
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2005). CAFs have fundamental functions for the growth of solid tumours since 
depletion of these cells in mouse tumour models induce tumour necrosis mediated by 
TNF-α and INF-γ (Kraman et al. 2010). 
Tumour cells as well as other cells presented in the TME produce factors like VEGF, 
PDGF, FGF, cytokines and chemokines that stimulates neovascularization by inducing 
endothelial cells and periocytes to produce new blood vessels a process called 
angiogenesis (Folkman 1971). An angiogenic switch in which the TME becomes 
dependent on nutrition and O2 from the formation of new blood vessels is an absolute 
requirement for continuous tumour expansion.   The vessels sprout produced in this 
process shows chaotic branching and leakiness resulting in increased tumour interstitial 
fluid pressure. Increased fluid pressure triggers unstable blood flow, oxygenation and 
distribution of nutrition and waste compounds in the TME. This, in turn, increases 
hypoxia and facilitates metastasis (Eltzschig and Carmeliet 2011). 
Reduced O2 levels seen during hypoxia induce a dramatic change in gene expression 
mediated by hypoxia-inducible factors (HIFs), which are composed of an O2-regulated 
HIF-α subunit (HIF-1α, HIF-2α, or HIF-3α) and a constitutively expressed HIF-1β 
subunit (Semenza 2012). During hypoxia the proteosomal degradation of HIF α 
subunits, mediated by O2-dependent prolyl hydroxylation, are inhibited leading to 
stabilization and rapid accumulation of HIF proteins (Kaelin and Ratcliffe 2008). 
Activation of HIF proteins results in altered transcription and expression of more than 
1500 genes that can induce angiogenesis, tumour cell aggressiveness, invasion and 
metastasis (Semeza 2012). 
 
1.7 Interactions with the immune system 
 
The immune system represents an important tool for the destruction of cancer cells and 
precancerous conditions in the human body. Malignant growing tumours have in most 
cases developed immune evasion strategies to avoid destruction by immune cells. As a 
result, immune cells infiltrating into the tumour sites are generally disabled to eliminate 
tumour cells. This ability to evade destruction by anti-tumour specific T cells has been 
accepted as an emerging hallmark of cancer (Hanahan & Weinberg 2011). Apart from 
suppression of cytotoxic immune cells, tumour-derived factors can induce the 
accumulation of inhibitory and regulatory immune cells including regulatory T cells 
(Treg) and suppressive cells derived from the myeloid lineage. These myeloid-derived 
suppressor cells (MDSC) comprise a heterogeneous group of immature cells, i.e. 
progenitors of macrophages, dendritic cells and granulocytes that are known to suppress 
T and NK cell functions (Gabrilovich and Nagaraj 2009). One essential immune 
evasion strategy that can be induced or applied by tumour cells is the formation of an 
inflammatory microenvironment.  Tumour cells can induce inflammation directly 
through oncogenes that induce transcriptional programs responsible for the production 
of pro-inflammatory eicosanoids, cytokines and chemokines that attract different cells 
of the immune system to the microenvironment (Johnsen et al. 2009). Also chronic 
inflammation caused by viral or microbial infections, autoimmune diseases, dietary 
products or inflammatory conditions caused by unknown reasons can create an 
inflammatory microenvironment that supports tumour growth (Mantovani et al. 2008).  
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It should be stressed that mouse immune xeno-recognition of human tumour grafts is 
fundamentally different from the patient immune recognition of the autologous tumour, 
and provides little information for the patient situation.  
The PSCT model is designed to avoid interference from the immune system using 
severely immunodeficient strains for the experiments. This allows for studies separate 
from most influence of the host immune xenoreactive immune system. To include 
interactions with effector arms of the human immune system in the PSCT analysis, a 
future option could be to reconstitute NSG mice with a human cellular immune system 
or specific immune components (Shultz et al. 2005). The methodology for hematologic 
reconstitution in humanized mice is however still under perfection and reconstituted 
immune cells are quantitatively/qualitatively weak failing to be maintained over long-
term, but improvements are reported  
 
1.8 Metastasis 
 
Metastasis, defined as the spread of cells from the primary neoplasm to distant organs, 
is known to be the main cause of death from cancer. Cancer, primary tomour and 
secondary leisions, consists of a heterogeneous population with a variety of genetic and 
epigenetic properties, some of these have the potential to gain a more aggressive profile 
and ability to metastasize (Chaffer et al. 2007). They may disseminate through EMT-
driven motility and angiogenesis mediated transportation to colonize a distant site. Thus 
the metastatic property is determined by capacity of individuals in a heterogeneous 
tumour population. (Fidler 2003; Heppner 1984) In xenografts models only as few as 
0.01% obtain this capacity and develops into metastasis. (Luzzi et al. 1998; Chambers 
et al. 2002) 
It was in 1929 proposed that metastatic dissemination occurs purely by mechanical 
factors as a result of the vascular system´s anatomical structure and that the vasculature 
system is key to metastatic transport and spread (Ewing 1928). A later publication by 
Folkman proposed that all tumours are angiogenesis dependent, this has strongly 
influenced the cancer field  (Folkman 1971).   
The ”seed and soil” concept (presented by Paget 1889) is a plausible explanation to 
tumour metastatic site selectivity, tropism. It has been defined that the tumour cells 
potential to metastasize depends on its interactions with the homeostatic factors that can 
promote survival, growth progression, the metastatic invasion and local angiogenesis. 
(Quail and Joyce 2013). The theory of ”seed and soil” proposes that metastasis depends 
on cross-talk between selected cancer cells (the ‘seeds’) and specific organ 
microenvironments (the ‘soil’) the conclusion is that metastases will only form when 
the seed and soil are compatible.  Components of the microenvironment appear to play 
a significant role in the metastatic process in several phases, ex, by altering MET/EMT 
at e pre-metastatic phase (Gao et al. 2012; Chao et al. 2012) or by preparing a pre-
metastatic niche.  To render the target metastatic-niche receptive to tumour 
colonialisation several components of the microenvironment are involved, increased 
numbers of fibroblasts (and potentially CAF), growth abundance of BM-derived cell 
types and secreted cytokines. According to this concept (Kaplan et al. 2005) published 
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that BM-derived VEGFR1 positive cells pre colonize the pre-metastatic-niche prior to 
tumour cell arriving at the site, this indicates a possible interaction and communication 
between the primary and secondary sites and their microenvironment actors.  
Thus it is crucial to achieve better understanding on systemic, cellular and molecular 
level. For clinical relevance it is in this context critical to consider both species and 
developmental aspects when looking for the relevant signalling.  
 
1.9 Cancer stem cells 
 
A small subpopulation of cells in tumours, so called cancer stem cells (CSC), have been 
described to drive malignant progression and repopulate the tumour after therapy. 
The concept of CSC is in many aspects overlapping with the definition of Tumour-
Initiating Cells (TICs), i.e. cell subtype with potential to initiate xenograft growth in 
animals (Easwaran et al 20014). It has been suggested that CSC/TICs are responsible 
for metastatic processes and therapy resistance/recurrence (Nyguyen et al. 2012, Beck 
and Blanpain 2013).  
The origin of the CSC/TIC is debated but has been suggested to arise in two alternative 
ways. Either from a normal stem cell with accumulated mutations becoming 
“cancerogenic” and keeping the stem cell properties. The other suggested path is that an 
adult differentiated cell accumulate genetic changes until it becomes tumourigenic and 
then furthermore acquires stem cell characteristics for immortalisation.  
 
 
 
 
Figure 8. Illustration of the interplay between the cancer cells and the tumour microenvironment 
components at metastasis. Reproduced from Quail and Joyce 2013 with permission from the publisher. 
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1.10 Treating cancer 
 
Today, and from the earliest historical documentations, surgery to remove tumours is a 
key component in cancer therapy. Access to appropriate anaesthetic agents is a 
prerequisite for more complex surgery to invasively remove tumours (Gilman 1963). 
The German physicist Wilhelm Röntgen made the discovery of the x-ray in 1895 
leading way to the idea to combine surgery with radiation. The era of cancer 
chemotherapy began in the 1940s with Studies by Louis Goodman and Alfred Gilman 
(Goodman et al. 1946; Gilman 1963) The fascinating history of cancer therapy 
development has been comprehensively described in “The Emperor of All Maladies; A 
Biography of Cancer” (Mukherjee 2011). New approaches and candidate drugs are 
rapidly emerging. Predicting the individual response to therapy is a challenge in the 
clinic. Reliable assays for this prediction is however sparse. There are several reasons 
for this; The heterogeneity of tumours and a lack of predictive markers for therapy 
response. This may be reflected in the high failure rate in clinical trials of new drug 
candidates in the field of oncology, in spite of preceding excellence in pre-clinical 
studies. Although the background for this is multifactorial, existing pre-clinical 
assessments have many drawbacks.  
 
1.10.1 Treating child cancer 
 
Treating child cancer is challenging given that childhood malignancies present 
differences in clinic and biology and that children presents challenges of the full 
biologic and physiologic development from the fetus to the adult. The majority of 
todays cancer therapies have a primary focus targeting proliferating cells resulting in 
severe effect on immature organs and developing structures, in particularly tumours 
located in CNS and next to rapidly growing normal tissue (Duffner et al. 1988, 
Jannoun and Bloom 1990) 
Dramatic improvement for pediatric malignancy in survival has been achieved in 
previous years (Figure 3) although advancements seems to be halted (Gustafsson et al. 
2013), However, toxicities are high and a significant proportion of patients remain 
therapy resistant. Young children are at particular risk for adverse side effects from 
treatment and survivors present a wide range of specific health problems (Oeffinger and 
Hudson 2004). Therefore improved targeting may prove to be beneficial for the patient 
both through better therapeutic efficacy, as well as the putative limitation of adverse 
long-term neurological side effects.  
 
1.10.2 Treating NB 
  
Although significant progress has been made with multi-modal therapies, children with 
high-risk neuroblastoma still have a 5- year survival rate around 50% (Maris 2010). 
Predicting favourable outcome is difficult, and improved stratification is clearly 
required to avoid both under- and overtreatment and better understanding chancer. 
Young children are at particular risk for irreversible adverse side effects. 
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Neuroblastoma patients are treated according to their risk-group to avoid and decrease 
excessive side effects and long term late effect (Cohn et al. 2009; Maris 2010). The low 
and intermediate risk group have a good 10-year event free survival. Unfortunately poor 
survival in high risk NB is motivating a more aggressive treatment regime with high 
dose and multimodal therapy, chemo before and after surgery including stem cell rescue 
and radiation.  
These patients may get a long follow-up therapy that includes immunotherapy 
combined with the retinoic acid.  For the high risk (metastatic) NB group available data 
motivate an increased intensity of induction therapy to improve outcome and response, 
particularly improved median progression free survival (Cheung and Heller 1991). 
 On the other hand there has been a trend to reduce therapeutic intensity for tumours 
with favourable biological profile. (Maris 2010) The trick is to at an early stage make a 
good categorization and prediction of the cancer, to prepare the optimal treatment 
strategy at start.   
Currently, different combinations of cytostatics are used as induction therapy, followed 
by attempts of radical surgery, high-dose myeloablative chemotherapy and autologous 
stem cell reinfusion, irradiation and maintenance therapy with differentiating retinoids 
and emerging immunotherapy as performed in novel protocols both in North America 
and Europe (Matthay 1999; Maris 2010; Ladenstein 2010). The current high-risk NB 
protocol in Europe, HR-NBL1/SIOPEN (Ladenstein 2010) is using a chemotherapy 
induction combining cisplatinum, carboplatinum, cyclophosphamide, vincristine and 
etoposide (COJEC) that is further combined with topotecan, vincristine and doxorubicin 
in case of lack of complete clinical response. 
 
 
Fgure 9. Chemotherapy induction for high-risk neuroblastoma in Europe (HR-NBL1/SIOPEN) using the 
COJEC regimen (cisplatin, carboplatin, vincristine, etoposide, cyclophosphamide) combined with TVD 
(topotecan, vincristine, doxorubicin) to obtain clinical remission for the randomization to high-dose 
therapy (depicted “R1” in the figure). Reproduced from Ladenstein et al. 2010 with permission from the 
publisher  
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Table 1. Overview of survivial of NB patients.  
Reproduced with permission from Maris 2010. Copyright Massachusetts Medical Society 
 
 
1.10.3 Doxorubicin  
 
Doxorubicin is a hydroxyl derivative of daunorubicin (Arcamone et al. 1969) 
discovered in the 1950´s. Daunomycin (daunorubicin) was the first anthracycline 
initially isolated from a strain of Streptomyces peucetius bacteria that produced the red 
pigmented antibiotic later named Doxorubucin  (Arcamone et al. 1969). This agent 
proved to be quite efficient, following research have brought forward an amount of 
other anthracycline antibiotics and analogues, as today there are over 2000s analogues 
of the prototype doxorubicin (Weiss et al. 1992). Doxorubicin is well-studied but the 
exact mechanism(s) of action has been debated. Doxorubicin may act through binding 
DNA-associated enzymes and interact with DNA base pairs, it has a range of 
molecular targets hence the multiple cytotoxic effects. Doxorubicin is known to 
effectively combat tumours with rapidly dividing cells and slow progressing cancer.  
Doxorubicin is included in the high-risk neuroblastoma treatment TVD combined 
with topotecan and vincristine (Garaventa et al. 2003; Ladenstein et al. 2010). 
Unfortunately the usage is dose limited due to toxicity, affecting most organs, 
inducing severe cardio toxicity (Oktay Tacar et al. 2012).  
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2 AIM  
 
Translational studies towards the understanding of tumour-host interactions are of 
outmost importance for developing enhanced therapies. For the most aggressive forms 
of tumours in children effective treatments will be attainable when the molecular events 
that are specific to childhood tumourigenesis are better understood.  
A central hypothesis behind the here presented approach is that compared to current 
animal models, the introduction of a homologous human tissue environment provides a 
more favourable setting for studying human tumours and evaluation of chemotherapy 
responsiveness/resistance.  
This doctoral thesis focuses on exploring the complex in vivo microenvironment of 
compartmentalised human embryonic tissues in the human pluripotent stem cell 
induced experimental teratoma (PSCT) model, and addresses the following questions: 
1. Does the PSCT milieu provide a relevant neoplastic niche for support of 
embryonic neuroectodermal tumours? 
 
In Paper I we have explored the model for in vivo growth support of NB cell lines. 
In Paper II the same questions were addressed for biopsy material from tumours of 
neural embryonic origin obtained directly from patients. 
With the ultimate aim to add further clinical relevance to pre-clinical modelling and 
assessment of therapy compared to current preclinical in vivo models, we asked the 
question: 
2. Can the PSCT milieu be used for a preclinical assessment of therapy response? 
 
In Paper III we test the PSCT milieu for assessing doxorubicin chemotherapy response 
towards neuroblastoma. 
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3 MATERIALS AND METHODS 
 
3.1. Flowchart of the experimental set up 
 
 
Figure 10.  Schematic illustration of the interacting procedures in the study, providing an overview of the 
experimental set up.   
 
 
3.2 Patient tumour material   
Specimens from patients undergoing surgery at the Karolinska University Hospital, 
departments of neurosurgery or paediatric surgery were used. An inclusion criterion 
was presence of a tumour genetic marker enabling a positive identification of cells, 
e.g. MYCN amplification, or Y-chromosome (the PSCT model is generated from 
female origin).  Information from the national tumour bank allowed precise molecular 
fingerprint markers on most tumours entering the study. Fresh tumour material was 
aliquoted, cryo-preserved, and thawed at chosen time points, aiding the logistics of 
the analysis. The logistics for transportation of tumour specimens from the clinic to 
the in vivo model and analysis is described in Paper 1. 
Fresh tumour material were aliquoted, cryo-preserved, and thawed at chosen time 
points, aiding the logistics of the analysis.  
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3.3 Tumour cell lines 
 
Neuroblastoma (NB) cell lines: [Papers I and III] Three Neuroblastoma cell lines 
IMR-32, SK-N-BE(2) and Kelly were used. The NB cell lines were obtained from 
ATCC. 
IMR-32: was derived from the abdominal tumour mass of a 13-month old 
Caucasian male neuroblastoma patient. The tumour line has an amplification of 
the MYCN gene and ALK, together with partial deletion of chromosome 1 
(Tumilowicz et al 1970; Caren 2008; Kryh 2011). 
SK-N-BE (2): was derived from the bone marrow metastasis of a disseminated 
NB after repeated cycles of chemotherapy and radiotherapy from a two year old 
child in 1972. The tumour has an amplification of MYCN and a mutation 
(C135F) in the tumour suppressor gene p53.  
Kelly: was derived from a brain metastasis of NB. It has MYCN amplification, 
gain of chromosome 17q, and deletion of 11q as major aberrations (Kryh 2011). 
 
All tumour cell lines were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) 
with 10% foetal bovine serum (FBS) and 1% penicillin/streptomycin (all from 
Invitrogen).  
The cell line identities were all confirmed using STR profiling at the Cancer Center 
Karolinska Core Facility service, Karolinska Institutet.  
Experiments were performed on Mycoplasma free cell cultures. Cells were regularly 
controlled EZ-PCR Mycoplasma Test Kit (Biological Industries). The cell culture 
supernatant was used for screening of cells that had stayed in same media without 
changing for 3 days. The PCR reaction mix was used according to the attached 
instructions, a positive control was provided by the kit. 
 
3.4 Pluripotent stem cells 
 
The human embryonic stem cell line HS181 was used for the experimental setup in 
papers I-III. It was originally derived from ICM (inner cell mass of a IVF blastocyst). 
The selected stem cells were initially cultured on Feeder cells (hFS / human fore skin 
fibroblasts) CRL-2429; ATCC – the feeder cells were mitotically inactivated by treating 
with mitomycin C (10µg/ml, 3hours). The hFS cells were seeded on 6 well plates 
(2x104 cells/cm2) from BD Falcon and cultured in IMDM (Iscove’s Modified 
Dulbecco Medium) supplemented with 10% foetal bovine serum (FBS) from Invitrogen 
with 1% PST (penicillin/streptomycin) from Invitrogen. For paper III, the HS181 
culture plates were instead pre-coated with truncated recombinant human vitronectin 
and cultured in Essential 8 media from Invitrogen according to manufacturer’s 
instructions (Invitrogen). Immunohistochemistry and Reverse Transcriptase-
Polymerase Chain Reaction (RT-PCR) were used for routine analysis of markers of 
pluripotency as described (Gertow et al. 2004). 
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3.5 Animals 
 
Male mice at the age 6-12 weeks, from severely immunodeficient strains were used for 
the experiments.  
The mice were kept at the MTC animal facility with ad libitum food and water, at 20-
24°C temperature, 50% relative humidity and a 14/10 hour light-dark cycle. The mice 
were monitored following all procedures, according to the ethical and mouse 
experimental regulations of Karolinska Institutet and to protocols in the ethical 
permissions. 
SCID beige mice (C.B.-17/GbmsTac-scid-bgDF N7).   (Papers I and II) 
The genetic profile of severe combined immunodeficiency (SCID)-beige mice includes 
the Beige mutation leading to defect macrophages and impaired NK-cell. The SCID 
mutation causes lack of both T and B lymphocytes. (Croy and Macdougal 1990). These 
mice were obtained from M&B, Denmark via the MTC animal facility, Karolinska 
Institutet.  
NSG mice (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ JAX® strain). (Paper III) 
The NSG strain represents today the most highly immunodeficient  mouse model; 
exhibiting absence of mature B, T cells and NK cells as well as having defective 
macrophages and dendritic cells and lacking complement (Shultz et al. 2005). The NSG 
mice from Jackson laboratories were obtained via the MTC animal facility, Karolinska 
Institutet. 
 
3.6	  In	  Vivo	  model	  –	  PSCT	  
 
Figure 11. The PSCT in vivo model 
 
3.6.1 Generation of experimental teratoma 
 
Experimental teratomas were generated by injection of 1x104 -1x105 HS181 cells (in 
50µl culture medium) under the testicular capsule with anaesthesia (3.0 % isofluran). 
HS181 cells were immediately prior to injection mechanically collected from the 
culture plate, re-suspended in medium and injected using a 1-ml syringe with 27G¾´´ 
Nr. 20 0.4-19mm grey needle (both from BD Falcon). For injection, the abdomen was 
opened with a small cut allowing access to the testis. For details of the surgical 
procedure, see Gertow et al 2007. The abdomen was closed with re-absorbable suture 
(Vicryl) and post-operative administration of Tamgesic was applied. Teratomas were 
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allowed to develop for 40-45 days resulting in mature experimental teratoma (Gertow et 
al 2004).   
3.6.2 Growth of human tumours to the PSCT model  
 
3.6.2.1  Transplantation of cell lines (Paper I, III)  
Tumour cell lines in logarithmic growth phase were harvested with enzymatic 
detachment (Trypsin, Invitrogen) and kept on +4° ice until injected. Cells were 
resuspended in cold PBS and transported to the surgery on wet ice (+4°C). 2x106 
million cells were injected in a volume of 50 µl centrally in the teratoma. For this a 
second operation was performed to access the testis/teratoma via the abdomen, similar 
to the surgery for the first implantation of HS181 cells. Two weeks later chemotherapy 
was started.  
3.6.2.2   Transplantation of clinical tumours (Paper II) 
After receiving fresh patient material the tumour was aliquoted into small pieces of 1-4 
mm, and when possible saved in liquid N2 for later injection, or alternatively injected 
fresh.  
Material for injection was transported to the animal facility on wet ice in medium. 
Small pieces of 1mm3 were inserted intact, or injected as cell suspension. The cell 
suspension was prepared by plunger of a 5-ml syringe (BD Falcon), and by filtering the 
cell suspension through a 70µm Nylon cell strainer (BD Falcon). The suspension This 
was injected with a 1ml-syringe (BD Falcon) and 27G¾´´Nr. 20 0.4-19mm grey needle 
(BD Falcon), similar to the procedure used for tumour cell lines. Table 1 illustrates an 
overview of the patient tumour material with diagnosis and clinical history for the 
patients in Paper II. 
 
 Diagnosis Stage History  Chr. 
Aberration 
Patient 1 Supratentorial 
peripheral 
neuroectodermal 
tumour (sPNET) 
Very 
aggressive 
irradiated and 
chemo 
2:nd relapse p53 mutation 
Patient 2 Pilocytic 
astrocytoma   
Low 
malignancy  
Primary tumour 
Hydrocephalous 
N/A 
Patient 3 Classic 
medulloblastoma 
Highly 
malignant 
Primary tumour p53 mutation 
Patient 4 Peripheral primitive 
neuroectodermal 
tumour (pPNET) 
Non--
irradiated 
Primary tumour EwS-Fli1 
translocation 
Patient 5 Neuroblastoma M (INRG) 
4 (INSS) 
First relapse. 
Metastasis in 
skull. 
 
11q- del 
Table 2: Details of surgical tumours included in Paper II. 
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3.7 Chemotherapy treatment (Paper III) 
 
Doxorubicin treatment: The animals were randomised into treatment groups and 
therapy started 14 days after tumour transplantation.  
Doxorubicin (Sandoz®; Ebewe) was diluted in PBS (DPBS GIBCO ™ Life 
technology) and administered by intraperitoneal injection at the indicated doses, 
4mg/kg 8mg/kg and 12mg/kg.  
Control animals were MOCK treated with an injection of PBS of equal volume. 
3.8 Euthinization 
 
Animals were sacrificed at the endpoint of the experiment, by cervical dislocation or 
using CO2 gas. Selected material was harvested for analysis.  
 
3.9 Tissue sampling 
 
Testis/teratoma/tumour was extracted and fixed in 4% PFA over night and transferred 
to 70% EtOH and then paraffin embedded (using the CCK core facility service). 
Additional organs (liver, gut and kidney) were preserved in some cases.  
The tissue was dehydrated through a series of alcohol to xylene in a standardized 
manner before paraffin embedding. Samples were sectioned on Super frost plus glass 
(menzelser or thermo scientific) into 5µm thick sections (= FFPE) for analysis.  
For further analysis some material was snap frozen in liquid nitrogen and saved in -
80oC. Suggested analysis for these frozen material was to extract RNA.  
3.10 Analysis 
 
3.10.1 Histology and morphology 
 
Hematoxilin & Eosin (HE) staining was performed on 5µm thick FFPE sections to 
provide a general overview of the tissue morphology. The Hematoxylin stains the 
nucleus blue and the Eosin binds eosinophilic structures providing a pink colour. The 
stained FFPE sections were scanned and the location of tumour growth, together with 
histological structures, were mapped using FISH and IHC, this way indicating areas of 
interest. Immunohistochemistry was extensively used in all papers. A panel of 
antibodies have been applied to identify different selected targets (listed below in 
Tables 2-5) 
 
Antibody Dilution Source 
Oct4 1:50 Chemicon, MAB4401 
Nanog 1:50 R&D, AF1997 
TRA1-81 1:50 Chemicon, ab90233 
TRA1-60 1:50 Chemicon, ab90232 
SSEA-4 1:50 Chemicon, ab90230 
 
Table 3. Antibodies used for indication of pluripotency in hESC. 
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Marker 
 
Source 
 
Dilution 
 
Secondary antibody detection 
 
B-catenin Invitrogen 18-0226 1:100 Bond Kit nr: DS9800 Lieca 
CD31 Dako M0823 1:200 Bond Kit nr: DS9800 Lieca 
CD99 NCL-CD99 1:50 Bond Kit nr: DS9800 Lieca 
CGA Neomarker MS324 1:800 Bond Kit nr: DS9800 Lieca 
E-cadherin NCL-E-CAD 1:40 Bond Kit nr: DS9800 Lieca 
Ki67 Ventana 790-4286 Ready to use UltraView Universal DAB  
NeuN Chemicon MAB377 1:50 Bond Kit nr: DS9800 Lieca 
NSE NCL-NSE-435 1:200 Bond Kit nr: DS9800 Lieca 
Synaptophysin NCL-L-SYNAP-299 1:400 Bond Kit nr: DS9800 Lieca 
Vimentin Dako M7020 1:400 Bond Kit nr: DS9800 Lieca 
NFP NCl-NF200-N52 1:50 Bond Kit nr: DS9800 Lieca 
 
Table 4. Antibodies used in Paper I  
 
 
 
 Antigen  Source  Dilution  2:nd detection 
 αSMA  Novocastra/leica, NCL -     
SMA 
1:50  DakoCytomation EnVision+System-HRP 
 CD31  DAKO, M 0823  1:20  DakoCytomation EnVision+System-HRP 
 CD44  DAKO, M 7082  1:50   DakoCytomation EnVision+System-HRP 
 Chromogranin A  DAKO, A 0430  1:2000  Bond Polymer Refine detection kit, Leica 
 Cripto 
  
 Rockland, 600-401-99337 
 
 1:400 
 
 4+ Biotinylated Goat Anti-Rabbit-IgG,  
 Biocase Medical 
 E-cadherin  Abcam, ab1416  1:50  Vectastain Universal Elite ABC 
 HIF2α  Novus Biologicals,  
 NB100-132 
 1:150  DakoCytomation EnVision+System-HRP 
 Ki67  Abcam, ab833  1:50  Vectastain Universal Elite ABC 
 Lefty  Santa Cruz, SC-7408 
 
 1:25 
 
 4+ Biotinylated Mouse Anti-Goat-IgG,  
 Biocase Medical 
 Nodal 
 
 Life Span BioScience,  
 LS-B3955 
 1:100  4+ Biotinylated Mouse Anti-Goat-IgG,  
 Biocase Medical 
 NSE 
 
 Novocastra/leica,  
 NCL-NSE-435 
 1:200  DakoCytomation EnVision+System-HRP 
 
 Synaptophysin 
 
 Novocastra/leica, NCL-L- 
 Synap-299 
 1:100  DakoCytomation EnVision+System-HRP 
 Tyrosinase  Leica, PA 0322  1:100  DakoCytomation EnVision+System-HRP 
 Vimetin  DAKO, M 7020  1:100  DakoCytomation EnVision+System-HRP 
 
Table 5. Antibodies used in Paper II  
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Antigen Source Dilution 2:nd detection 
Ki67 Abcam 
AB:833-500.Rabbit pk ab.   
Lot 713408 
1:50 Vectastain Universal Elite  
DAB- ABC  
Caspase-3 BD-Pharamingen 
Purified rabbit anti-active 
caspase-3 
Cat: 559565 
1:1000  Vectastain Universal Elite ABC 
HuCD34 DAKO  
mouse Anti-Human  
CD34 ClassII.  
m.ab; M 7165. 
 
1:500 
1:50 
Jackson Immunoresearch laboratory  
IF: Cy3 goat anti mouse  
IHC : DAB,  
Vectastain Universal elite, ABC 
 
Table 6. Antibodies used in Paper III  
 
 
Paraffin-embedded pre-baked material sectioned in 4µm on superfrosted glass slides 
were used for these experiments. The antibodies included generally had different 
optimization protocols including different pre-treating steps and solutions. Antigen 
retrieval was performed with either boiling in high pH buffer (like Tris-EDTA buffer or 
DAKO pH9 buffer) or low pH buffer (for example Citrate buffer) enzymatic treatment 
with weak HCl and pepsin was common, however in some cases no pre-treatment was 
needed. (Details are defined in the respective papers) regarding specific conditions and 
secondary detection system applied, (Papers I-III).  
 
Analysis using Fluorescent in situ hybridization (FISH) was a key tool in the performed 
studies. This was used to separately identify human PSCT and engrafted tumour cells in 
the model. FFPE sections from tumour xenografts were used as positive control in 
FISH experiments. 
 
The following FISH probes were used (all from Abbott Molecular/Vysis); 
A. FISH probe - Spectrum Red labelled total human genomic DN 
B. FISH probe - CEP X SpectrumOrange CEP Y SpectrumGreen 
C. FISH probe - LSI n-myc, 2p24  Spectrum orange 
D. FISH probe - LSI n-myc, 2p24  Spectrum Green/ CEP2 Spectrum orange  
 
Probe A. was used to human confirm origin of the formed embryonic tissues in PSCT. 
Probe B. was used to detect the X (PSCT cell) and Y-chromosome (engrafted male 
tumour cell).  
Probe C. was used to detect tumours amplified MYCN, but not for LSC analysis . 
Probe D. was primary used for LSC analysis of MYCN in SKNBE2.  
 
The protocol for FISH analysis was carried out strictly according to the manufacturers 
instructions (Vysis protocol). In brief, the procedure included deparaffinized using 
xylene, rehydration using a series of Ethanol and water. Antigen retrieval with boiling 
in Citrate buffer (pH 6.0) and 0.01% HCL+pepsin at 37°C for 5 min. Denaturation of 
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double-stranded DNA at 75°C for 5 min and probe hybridization at recommended 
temperature (either 38°C for NMYC or 42°C for X/Y) overnight. SSC solution was 
provided by the vysis kit. Final fixing of sections with Vectasheild HardSet Antifade 
mountingmedia with DAPI. 
 
 
3.10.2 Image analysis  
 
Image analysis was performed using a Zeiss Axiovert 200M microscope and software 
from QCapture and Openlab. 
 
FFPE slides were scanned using a Hammamatsu scanning system NDP SCAN 2.0.   
 
High throughput screening of single cells of PSCT FFPE tissue specimens was 
performed using a CompuCyte LSC 2 Laser Scanning Cytometer equipped with 2 
lasers (488nm and 633nm) and using the WinCyte 3.7 software (CompuCyte). 
 
3.10.3 Statistical analysis 
 
Statistical analysis: This was performed using one-way analysis of variance (ANOVA). 
The Bonferroni correction was applied to adjust for multiple testing. The GraphPad 
Prism 6.0 software was used for testing normal distribution and for the generation of 
graphs.  
 
 
4 ETHICAL PERMISSIONS 
 
The work was conducted with approved ethical applications: 
Permissions number 514/00 and 2008/307/31 obtained from the Local Ethics 
Committee at Karolinska Institute. 
Permissions number N105/07, N112/09, N173/10, N101-13 and N118/14, from 
the Stockholm Northern Animal Review Board. 
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5 RESULTS and DISCUSSION 
 
5.1 Paper I  
Neuroblastoma Cells Injected Into Experimental Mature Teratoma Reveal A 
Tropism For Embryongic Loose Mesenchyme.   
Seema Jamil, Jessica Cedervall, ISABELL HULTMAN, Rouknuddin Ali, Naira V. 
Margaryan, Agnes Rasmuson, John Inge Johnsen, Baldur Sveinbjörnsson, Tina 
Dalianis, Lena Kanter, Abiel Orrego, Luigi Strizzi, Mary.J.C. Hendrix,  Bengt 
Sandstedt, Per Kogner, Lars Ährlund-Richter 
Published in the Int J Oncology. 43: 831-838. 2013. 
 
BACKGROUND and AIM: Earlier studies in our research group have raised the 
possibility that the embryonic microenvironment in PSCT could be particularly well 
suited for studies on neural childhood tumours. This study aim to answer the question; 
Can the human non-malignant embryonic process in stem-cell induced mature 
experimental teratoma function as an in vivo microenvironment for studies of the 
growth of childhood neuroblastoma (NB) cell lines? 
APPROACH: Three human NB cell lines, IMR-32, Kelly and SK-N-BE(2), were 
compared for growth patterns in the PSCT model and when injected as xenografts.  
 
RESULTS and DISCUSSION: Proliferative index for each NB cell line was similar in 
both models, and growth was readily detected from the three cell lines showing 
histology of a poorly differentiated NB tumour with variable amount of fibrovascular 
stroma. NB cells were in the PSCT model found integrated in embryonic loose 
mesenchymal stroma and never observed in areas with well-differentiated somatic 
tissue i.e. bone, muscle, gut or areas of other easily identifiable tissue types. Histology 
recapitulated NB native presentation in patients. As expected, a perivascular preference 
was observed for the instigation of NB colonies.  
The tissue selectivity of the microcolonisation of NB with strong preference to loose 
mesenchymal stroma is intriguing. This tropism may be due to e.g. i) the open 
contextual nature of mesenchyme providing space, ii) the rigidity of present ECM 
providing physical cues, or iii) presence of potential developmental cues that could 
attract and promote integration. The latter option is particularly intriguing since 
embryonic mesenchyme is rich in neurotrophic factors and their receptors, with 
potential to support cancer / stem cell like growth.  
Aggressive IMR-32 tumour growth showed expression of the TGFβ superfamily 
member Nodal and its co-receptor Cripto-1, but not the Nodal antagonist Lefty, 
concurring with Nodal pathway regulation in early embryonic patterning. 
SIGNIFICANCE. We conclude that mature PSCT provide an embryonic niche well 
suited for further in vivo studies of NB. The observed tissue tropism provide a clear 
advantage towards conventional xenograft studies with possibilities to explore cues that 
attracted or promoted the microcolonisation of NB in human stroma. 
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5.2 Paper II  
 
Tropism Of The In Situ Growth From Biopsies Of Childhood Neuroectodermal 
Tumours Following Transplantation Into Experimental Teratoma 
 
Seema Jamil, ISABELL HULTMAN, Jessica Cedervall, Rouknuddin Q. Ali, Gabriel 
Fuchs, Bengt Gustavsson, Jurate Asmundsson, Bengt Sandstedt, Per Kogner, Lars 
Ährlund-Richter. 
Published in the Int. J. Cancer. 134:1630–1637. 2014. 
 
BACKGROUND and AIM:  In Paper I we demonstrated how the PSCT model could 
provide an experimental human in vivo model for neuroblastoma using NB cell lines. 
Here we explore whether the model also provides a relevant neoplastic niche suited for 
transplantation studies, of surgery-material from patients with primitive 
neuroectodermal tumours 
 
APPROACH: Five tumour specimens were analysed for growth after transplantation 
to the PSCT model and after injection as xenografts. Tumours included; Supratentorial 
primitive neuroectodermal tumour (sPNET); Pilocytic astrocytoma of the brainstem; 
Classic medulloblastoma; peripheral primitive neuroectodermal tumour (pPNET) or 
neuroblastoma (NB), respectively, was transplanted to the PSCT model. 
Each patient specimen was transplanted into 2-6 separate PSCT.   
RESULTS and SIGNIFICANCE: 
This study demonstrated that biopsies from childhood neuroectodermal tumours could 
instigate microcolonies in specific embryonic components of human experimental 
teratoma.  
Engraftment was detected in PSCT for three of the five transplanted tumours (pPNET, 
sPNET, and NB) after analysis of up to 120 FFPE sections of each PSCT. Protruding 
growth from the latter two tumours were detected, and selected for detailed 
examination. The failure to find engraftment could be due to lack of growth from the 
tumour, but it is important to note that for technical and resource reasons only small 
portions of the PSCTs were analysed. Likely, additional growth can be detected in 
further analysis of the material. Small biopsies (1mm) were allowed to grow for limited 
time (one month). When transplanted as xenografts no palpable growth was observed 
after four months. Similar to results from NB cell lines, a strict tissue tropism with a 
non-random integration into embryonic structural compartments was observed 
confirming for a clinical neuroblastoma engraftment into loose mesenchyme.  For the 
sPNET tumour, instead we found exlusive intergration into areas of neural 
condensation. Also, tumour colonisation showed a perivascular preference resulting in 
histology closely recuperating observations for the original patient tumour. Although 
the original tumour histology was kept, when tested for a panel of markers the NB lost 
IHC expression of neuroendocrine markers, Synaptophysin, NeuN, NFP, NSE.  In 
contrast, an sPNET tumour showed preserved histology and marker profile.  
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5.3 Paper III  
 
Chemotherapy Resistance In Microcolonies Of Neuroblastoma Analysed In 
Homologous Embryonic Tissue Environment In Vivo. 
 
Hultman I, Rognmo I, Jansson Edqivst J, Blomberg E, Pernicová Z, Björk L. Ali R, 
Phillips, L, Sandstedt B, Kogner P, Ährlund-Richter L. 
 
Manuscript 
 
AIM: Chemotherapy is widely accepted as part of first-line therapy for high-risk 
paediatric neuroblastoma (NB). The goal of this study was to examine in situ tumour 
chemotherapy responsiveness/resistance, using a previously developed human 
embryonic model for NB. 
BACKGROUND: Childhood cancers show fundamental differences to most common 
adult solid tumours in their cancer-causing genetics, cell biology and their local tissue 
microenvironment. Effective treatments will be attainable when the molecular events 
that are specific to childhood tumourigenesis are better understood. However, it is in 
this context critical to consider both species and developmental aspects when looking 
for the relevant signalling.   
APPROACH: We report for the first time in situ studies of neuroblastoma 
chemotherapy responsiveness/ resistance performed in a homologous embryonic in vivo 
microenvironment.  
Two well characterised paediatric neuroblastoma cell lines; IMR-32 and SK-N-BE(2) 
were transplanted to an in vivo model comprising a benign experimental teratoma, 
generated from human diploid bona fide pluripotent stem cells (the PSCT model) in 
NSG mice. Fourteen days after inoculation of two million tumour cells, emerging 
neuroblastoma micro-colonies were subjected to chemotherapy intraperitoneally with 
the topoisomerase inhibiting anthracycline doxorubicin. Twelve and 96 hours later the 
total PSCT with neuroblastoma growth and its surrounding human tissue environment 
were removed and assayed in formalin-fixed paraffin-embedded sections. We used a 
combination of conventional immunohistochemistry (IHC) and cytology to measure 
proliferation, apoptosis and cell death. A high throughput single cell screening system 
using laser scanning cytometry (LSC) to measure chemotherapy-induced changes of 
nuclear DNA index (sub G1 fraction) was also applied. 
RESULTS and DISCUSSION: The efficacy of microcolonisation and expansion of 
NB colonies in homologous embryonic stroma were similar to previous studies using 
cell lines. The results demonstrated a dose dependent response of NB cells to a single-
dose regimen of doxorubicin (chemotherapy drug belonging to the anthracycline 
group). 
The strongest anti-NB effects were observed from a recurrent treatment of 4+4 mg/kg 
doxorubicin given with a 48 hours interval. Administration of the same total dose, 
8mg/kg, as a single injection appeared less effective for both NB lines.   
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Following a recurrent doxorubicin regimen (repeated administration with 48h interval), 
we observed the presence of an asynchronous cellular response within individual 
tumour colonies, with cells exhibiting cytotoxic effects or enhanced proliferative index.  
The toxicity from the administered doses of doxorubicin on non-malignant PSCT 
tissues was assessed on embryonic tissues with high mitotic activity, i.e. embryonic 
neural epithelium, cartilage and muscle. Selectivity for transplanted NB cells over non-
malignant PSCT cells was observed for all tested doxorubicin regimens.  
SIGNIFICANCE:  
This study illustrates how chemotherapy outcome may be monitored in a pre-clinical 
assay in a homologous in vivo setting. 
These findings illustrate the feasibility of the approach and are a encouraging for 
clinically relevant further studies of patient material, regarding intra tumour 
heterogeneity and asynchronous response to therapy, of neuroblastoma and other 
primitive neuroectodermal tumours originating early in life. 
The illustration of a heterologous and asynchronous response after recurrent 
doxorubicin treatment is intriguing and may be of importance for the understanding of 
tumour resistance. 
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6 CONCLUSIONS 
 
We conclude that the homologous complex microenvironment with compartmentalised 
embryonic tissues in human experimental teratoma (the PSCT model) can provide: 
 
1. PSCT presents a novel human in vivo model for neuroblastoma, (Paper 1) 
 
o Structural components of the embryonic process in stem-cell induced teratoma 
supply an experimental in vivo microenvironment for the instigation of 
microcolonies of injected childhood neuroblastoma (NB) cell lines. 
o Microcolonisation showed a tissue tropism, with specificity to embryonic loose 
mesenchyme.  
o Individual variations in molecular profiles for the three neuroblastoma cell lines 
were observed, providing additional information on the neuroblastoma tumour 
biology. 
 
2. PSCT presents relevant in vivo neoplastic niches for studies on invasion and 
microcolonisation of primitive neuroectodermal tumours originating early in 
life (Paper II) 
o Transplantation of biopsies from childhood neuroectodermal tumours showed 
microinvasion into specific embryonic components of human experimental 
teratoma. The tumour progression in the model showed striking similarities to the 
tumour conditions in the young patient, maintaining most of their original 
characteristics.   
o Histological examination revealed a tropism with nonrandom integration into 
morphologically identifiable tissues. 
 
3. PSCT presents a model for in situ evaluation of early outcome parameters and 
death of tumour cells following chemotherapy of solid tumours (Paper III). 
o This study illustrates how chemotherapy outcome may be monitored in a pre-clinical 
assay. It was possible to measure dose dependent and diversified responses to 
doxorubicin chemotherapy. 
o The illustration of a heterologous and asynchronous response after recurrent 
doxorubicin treatment is intriguing and may be of important for understanding of 
tumour resistance. 
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7 FUTURE PROSPECTS  
 
Building on the proof of concept presented in this thesis, it is now important to ensue 
detailed studies on the interplay of tumour and human microenvironment. This would 
address if, or how, signalling pathways differ between tumour xeno-interactions and 
homologous interactions with surrounding tumour microenvironment. Such studies 
could reveal important information in the quest for new targets in therapeutics. 
 
The PSCT model provides theoretically not only an opportunity to study homologous 
interactions but also to generate an autologous system. We have in a collaborative study 
with the KI Biobank and Dr Anna Falk, KI, derived iPSC from two young patients with 
MYCN amplified NB, using skin fibroblasts. These will next be used to perform similar 
experiments as presented in this thesis, but in an autologous setting.   
 
Moving from cell lines to patient tumour material is also a goal. Here, it is important to 
broaden the repertoire of tested tumour types and to increase the numbers of tested. 
Partly, this is already on going. A total of 5 additional patient tumour materials have 
been collected, including material from 3 male patients diagnosed with high risk NB. 
These have been grafted to the PSCT (fresh and frozen/thawed) and subjected to 
chemotherapy (Table 7). 
 
 
 
 
Table 7. Overview of additional un-published studies on patient material.  
 
 
 
 
 
 
 
 
Patient number pat. 1 pat. 2 pat. 3
Ganglioneuroblastoma, 
 intermixed subtype
Age at biopsy 23* 45* 10y 8m*
Survival 21*+ 12*+ 11*+
Outcome NED 2015 NED 2015 In remission 
 Treatment High-risk protokoll Rapid-Cojec + TVD High-risk protokoll
Chromosomal abberations 11-q deletion, 17q + MYCN amplified 11-q  del, MYCN unknown
Total nr of injected PSCT 11 8 6
Fresh tumour NT 1 2  -
Fresh tumour +DOX treatment 4 (4mg/kg DOX) 2 (4+4mg/kg DOX)  -
Thawed tumour NT 3 2 3
Thawed tumour +DOX treatment 3 (8mg/kg DOX) 2 (4+4mg/kg DOX) 3 (4+4mg/kg DOX)
Findings Analysis ongoing            
Growth identified in one PSCT 
Analysis ongoing Analysis ongoing
All patients included were males, diagnosed tumor at stage 4 and metastasis present at sampling
*M=months. Y=years
INSS: International Neuroblastoma Staging System Committee system.  
INRGSS: The International Neuroblastoma Risk Group Staging System.
NED: No evidence of disease; DOX: doxorubicin; NT:not treated; TVD: topotecan, Vincristine, doxorubicine
Diagnosis Highrisk  neuroblastoma Highrisk neuroblastoma
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Stina, Tilde, Eftichia, Petra, Tinny, Jeanette, Vanessa, Matilda, Elina, Maryam.   
And to my dearest Dance Teachers for giving me that energy and joy so needed. 
Veronica Tjerned (Kathak) and Sunita Singh (Bollyood) Agnes Gagge (persian)  
 
 
 
 
Finally I wish to send my deepest thank you to  ❤ 
Richard Tjerngren - for being my most beloved.  
There are no words to describe how important you have been to me, especially at this 
time. You are truly the best friend in life, to have stood by my side in many years 
through better and worse and help me survive all that has been and enjoy all that is. 
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